A microfluidic platform is presented which fully automates all incubation steps of a three-stage, multiplexed magnetic bead immunoassay, such as the Luminex xMAP technology. Magnetic actuation is used to transfer the microbeads between adjacent laminar flow streams, and extended incubation channels allow sufficient bead incubation times (1 to 30 min., commonly 5 min. per stage) to enable high-sensitivity. The incubation steps are completed in succession within the device with no operator interaction, and the continuous flow operation requires no external fluidic controls. This technology enables rapid automation of magnetic microbead assays, and has the potential to perform continuous concentration monitoring.
INTRODUCTION
The popularity of microbead assays for research and clinical use has been growing due to their advantages over traditional assays such as ELISA. Assays such as the Luminex xMAP technology have been shown to enable a wider dynamic range and faster turnaround times than ELISA while providing similar sensitivity for low concentration samples. Most significantly, microbead assays allow multiplexing, where multiple analytes can be measured within the same sample volume, which drastically reduces cost and increases throughput for multiple analyte detection. These microbead assays are processed in a similar fashion to traditional assays, either in well plates or sample tubes using manual or robotic pipetting. The use of pipetting to transfer fluids has inherent drawbacks when attempting to work with small fluid volumes. These techniques are also time consuming as well as labor and skill intensive. Our microfluidic assay platform performs the incubation and wash steps of magnetic microbead assays autonomously. The microbeads are transferred directly from one incubation stage to the next without operator interaction. The self-contained automation offers benefits such as faster assay turnaround time since the transfer time between incubations is reduced to zero, less room for operator error, and reduced need for specialized operator skill. It also allows for continuous monitoring of analyte concentrations from a native sample stream such as blood or cerebrospinal fluid (CSF), a feature which is not offered by any immunoassay technology currently on the market.
THEORY
It has previously been demonstrated that a continuous flow microfluidic chip could perform the incubation steps of a multi-stage antigen sandwich immunoassay using paramagnetic microbeads [1, 2] . In this arrangement, the microbeads are coated with a monoclonal antibody with specificity to the antigen of interest before the assay begins. In the first stage of the assay, the microbeads are incubated with the sample, and they are subsequently bound with an amount of antigen which is correlated to the sample concentration. In the second stage, a fluorescently tagged second antibody which also has specificity to the antigen of interest is incubated with the beads. The fluorescent intensity of the microbeads after the two incubation steps is thus correlated to the sample concentration.
Assay Operation The Luminex xMAP technology has been chosen in this work due to its multiplexing abilities. For magnetic microbead xMAP assays, up to 50 simultaneous analytes can be detected in one sample. This is accomplished using a fluorescent colorcoding system where two additional fluorescent tags are added to each bead to code for a specific analyte. The intensity of each of these fluorescent tags is used to locate the microbead on a two dimensional grid such that it can be identified during detection. This coding scheme is illustrated in Fig. 1 . The Luminex assay uses a three-stage incubation approach. The first stage captures the antigen of interest by again incubating the monoclonal antibody coated microbeads with the sample, where the amount of bound antigen on each microbead after incubation is correlated to the sample concentration. In the second stage the beads are incubated with a biotinylated secondary antibody to the antigen of interest. Finally, in a third stage the microbeads are incubated with a streptavidinphycoerythrin conjugate to fluorescently tag to detection antibody. The threestage microbead assay is depicted in Fig. 2 . As in the two-stage assay, the fluorescent intensity of each bead is correlated to the antigen concentration in the sample. The sample concentration, as well as the color-coded identifier, are detected via flow cytometry. Microdevice Operation The microfluidic assay depends on a magnetic separation scheme where microbeads are pulled from one reagent stream to the next by external magnets (Fig. 3) . The device presented uses three layers to perform the three stage assay. The first layer has two inlets which create a laminar flow pattern between the initial bead carrier solution and the antigen sample in a common channel. An external permanent magnet pulls the beads across the flow boundary into the antigen stream. As the channel progresses, the initial bead solution is diverted to waste while the beads continue with the antigen stream into an incubation spiral. A second spiral on the same layer balances the flow resistance to control the amount of fluid which is diverted to waste. The beads then transfer to the second layer where the process is repeated with the secondary antibody, and then repeated once again in the third layer with the fluorescent tag.
EXPERIMENTAL
Chip Fabrication The chip was fabricated by standard soft lithography of PDMS. The three layers are cast separately on SU-8 photoresist patterned substrates. The tubing connection ports and layer transfer holes are punched through each layer with a sharpened 19 gauge needle. Alignment is done by eye, where only the layer transfer hole requires precision, and there is a ± 0.25 mm tolerance on this alignment. The top layer is bonded to the middle layer with corona discharge activation and heating to 100 °C for 1 hr. The middle layer ports are punched through the first layer to allow insertion of tubing at the chip surface. The lower layer is then bonded to the topmiddle complex and its ports are punched through the upper layers. Finally, a 75 mm by 25 mm glass microscope slide is bonded to the bottom of the lower layer. A location for the magnet is cut out with a razor blade such that the magnet is pressed into the material for retention. Tubing is pressed into the punched holes, which provides a sealed connection. The device layout and a photograph of a complete microdevice are shown in Fig. 4 .
Experimental Procedure Reagents for the experiment are taken directly from the Bio-Plex Pro Magnetic Cytokine Assay (Bio-Rad, Hercules, CA). For the experiments described, a two-plex assay was used with specificity for TNF-α and IL-6. The reagents are prepared somewhat differently from the assay instructions to optimize them for microdevice infusion. 100 µl of each microbead stock is mixed in a microcentrifuge tube, washed twice with Wash Buffer, and suspended in 600 µl of Ficoll-Paque Plus (GE Healthcare) for density matching such that the microbeads do not sediment after vortexing. 75 µl of each detection antibody stock is mixed with 600 µl of antibody diluent. 6 µl of phycoerythrin fluorescent tag stock is mixed with 600 µl of Assay Buffer. The provided wash buffer is used for the microdevice wash stream. The device is first infused via syringe pump with a mixture of PBS with 0.01% BSA until all channels are filled. The reagents are then infused using two syringe pumps, one for the magnetic microbeads, detection antibody, fluorescent tag, and wash buffer, and a second for the sample syringe which is replaced repeatedly throughout the experiment. All flow rates are 1 µl/min. After a new sample syringe is attached, there is a 20 minute flush time, followed by 15 minutes of bead collection. The collected beads are diluted with 100 µl of Assay Buffer, transferred to a well plate, and processed in the Bio-Plex flow cytometer for fluorescence quantification. All samples were created by serial dilution of the provided Bio-Plex standards, and are in the general range of 1 pg/ml to 1000 pg/ml.
RESULTS AND DISCUSSION
As shown in the first plot of Fig. 5 , the mean fluorescent intensity of the microbeads increases with both the sample analyte concentration and the incubation time. This was tested using bench-top incubations of the Bio-Plex assay with the provided standards, changing only the incubation times from the recommended procedure. Since a shorter total assay time is desirable for fast assay turnaround as well as for real-time monitoring, a 5 minute per stage incubation time was chosen as a compromise between incubation time and assay sensitivity. This time was then used for both bench-top (off-chip) and on- chip assays to compare their performance. As shown in the center and right plots of Fig. 5 , the on-chip and off-chip assays yield similar bead fluorescence intensities at a given antigen concentration. In both cases, the two analytes were quantified simultaneously using the assay's multiplexing feature. This data demonstrates that it is possible to use this microfluidic device as an automated platform for processing multiplexed microbead assays.
Given the complete three-stage incubation time of 15 minutes, the microfluidic assay could be applied to continuous monitoring applications where 20 minutes of lag time is acceptable. This analysis delay still offers advantages over assays commonly used for clinical testing which can range from hours to even days for immunoassays, while providing not only short lag times but also very high sampling rates as beads and sample are continuously infused into the device. If higher sensitivity is needed, the incubation times can be lengthened to as much as 25 minutes per stage by reducing the flow rate, at the expense of increased lag time, which will provide detection limits below 1 pg/ml. Continuous monitoring can be enabled by integrating the microfluidic assay with a flow cytometry system and software to compute a moving average of bead intensities. This system could be applied to clinical applications such as monitoring inflammatory cytokines in the blood during surgeries to improve surgical methods and enable personalized medicinal approaches to reduce damaging systemic inflammation. No currently available assay is capable of providing cytokine concentrations at high sampling rates during clinical procedures.
The microfluidic assay can also be used for rapid turnaround automated assaying. With a supporting fluidic control system, samples could be infused for 5 minutes each back-to-back, and the flow cytometry system could quantify each 5 minute step at the device output with precise timing. This implementation could be used in both clinical and research settings when individual samples or small batches of samples must be quantified for one or more proteins with high turnaround. The assay can also be used with custom monoclonal antibodies to measure any protein of interest.
CONCLUSION
This work has demonstrated a robust laboratory automation platform using microfluidics to execute important microbead assays. The platform works with existing off-the-shelf reagents for a large variety of clinical and life science testing applications, and customizable reagents are currently available which allow detection of any protein. This highly versatile technology enables automated assaying with multiplexing and high sensitivity without the need for large robotic systems or complex external actuators. It is especially well suited for applications where a small number of samples must be assayed with rapid results, and where continuous concentration monitoring is required. Future work will involve combining the microfluidic platform with a flow cytometry system to include automation of the detection step and to demonstrate continuous monitoring.
